|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0087111,
umls-concept:C0123931,
umls-concept:C0205179,
umls-concept:C0205251,
umls-concept:C0242957,
umls-concept:C0282460,
umls-concept:C0338204,
umls-concept:C0728747,
umls-concept:C1514559,
umls-concept:C1527249,
umls-concept:C1549649,
umls-concept:C2349209
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-1-11
|
|
pubmed:abstractText |
To determine the response rate of trastuzumab and irinotecan in HER-2/neu overexpressing advanced colorectal cancer (CRC), determine the frequency of HER-2/neu expression in CRC, and evaluate the pharmacokinetics of trastuzumab in a phase II study.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0735-7907
|
|
pubmed:author |
pubmed-author:BrufskyAdamA,
pubmed-author:ChenHelen XHX,
pubmed-author:EarleMartinM,
pubmed-author:EvansTerryT,
pubmed-author:FinkelsteinSydneyS,
pubmed-author:HwangJimmy JJJ,
pubmed-author:RamanathanRamesh KRK,
pubmed-author:RomanL JLJ,
pubmed-author:SafranHowardH,
pubmed-author:SinicropeFrank AFA,
pubmed-author:TroetschelMonicaM,
pubmed-author:WalkoChristineC,
pubmed-author:WongMichael KMK,
pubmed-author:ZamboniWilliam CWC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
858-65
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15641483-Adult,
pubmed-meshheading:15641483-Aged,
pubmed-meshheading:15641483-Antibodies, Monoclonal,
pubmed-meshheading:15641483-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15641483-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15641483-Camptothecin,
pubmed-meshheading:15641483-Colorectal Neoplasms,
pubmed-meshheading:15641483-Female,
pubmed-meshheading:15641483-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15641483-Humans,
pubmed-meshheading:15641483-Male,
pubmed-meshheading:15641483-Maximum Tolerated Dose,
pubmed-meshheading:15641483-Middle Aged,
pubmed-meshheading:15641483-Receptor, erbB-2,
pubmed-meshheading:15641483-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.
|
|
pubmed:affiliation |
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA. ramanathanrk@msx.upmc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
